Control method of local release for target compounds by using patterning hydrogel to nanoporous membrane

Patent metadata

Field	Value
Publication number	US-12558322-B2
Application number	US-202318153590-A
Country	US
Kind code	B2
Filing date	Jan 12, 2023
Priority date	Jun 26, 2018
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

Provided is a method of controlling local release of target compounds by patterning a hydrogel carrying a bone morphogenetic protein or anticancer drug as the target compounds onto an electrospun nanoporous membrane. The hydrogel is capable of controlling local release of the bone morphogenetic protein or anticancer drug as a carrier of the bone morphogenetic protein or anticancer. And the electrospun nanoporous membrane performs a basic function of the membrane of preventing infiltration of connective tissue. Thus, there is an advantage in that the hydrogel patterned nanoporous membrane can facilitate generation of controlled bone in a local region and degradation of cancer in a local region.

First claim

What is claimed is:

1 . A method of controlling local release of target compounds containing a bone morphogenetic protein or anticancer drug by patterning a hydrogel onto an electrospun nanoporous membrane, wherein the patterning of the hydrogel onto the electrospun nanoporous membrane includes:
(S1) preparing a micromold with a plurality of concave grooves; (S2) pouring a hydrogel solution comprising the target compounds into the micromold; (S3) filling the plurality of concave grooves on the micromold with the hydrogel solution; (S4) covering an electrospun nanoporous membrane on the micromold filled with the hydrogel solution, (S5) patterning a hemispherical hydrogel onto the electrospun nanoporous membrane by crosslinking the hydrogel onto the electrospun nanoporous membrane; and (S6) detaching the micromold from the hemispherical hydrogel patterned electrospun nanoporous membrane, wherein the electrospun nanoporous membrane is manufactured by an electrospinning process using polyurethane and Poloxamer 407 dissolved to a concentration of 10% (w/v) and 10% (w/v) of solvent, wherein the hemispherical hydrogel is at a concentration selected from the group consisting of 2.5% (w/v), 5% (w/v), 10% (w/v) and 15% (w/v), and wherein the hemispherical hydrogel is configured to control release of the target compounds based on the hydrogel concentration.

2 . The method according to claim 1 , wherein the hydrogel contains the target compounds and at least one of gelatin methacryloyl (gel-MA), hyaluronic acid, Na-alginate and hyaluronic acid methacrylate (HAMA).

3 . The method according to claim 1 , wherein the target compounds are at a concentration selected from 1-2000 ng/mL.

4 . The method according to claim 1 , wherein the electrospun nanoporous membrane has the surface wettability as the contact angle 82.89±1.3°.

5 . The method according to claim 1 , wherein the cross-linking is executed by exposing the hydrophilic functional groups of the hydrogel and the electrospun nanoporous membrane to a UV light at a wavelength of 360 nm and an intensity of 10,000 mW/cm 2 ,
wherein the hydrophilic functional groups of the hydrogel are selected from the group consisting of —OH, —COOH, and —NH, and wherein the hemispherical hydrogel is patterned onto the electrospun nanoporous membrane.

6 . A method of controlling local release of target compounds containing a bone morphogenetic protein or anticancer drug by patterning a hydrogel onto an electrospun amphipathic nanoporous membrane,
wherein the patterning of the hydrogel onto the electrospun amphipathic nanoporous membrane includes: (S1) preparing a micromold with a plurality of concave grooves; (S2) pouring a hydrogel solution comprising the target compounds into the micromold; (S3) filling the plurality of concave grooves on the micromold with the hydrogel solution; (S4) covering a hydrophilic layer of electrospun amphipathic nanoporous membrane on the micromold filled with the hydrogel solution, (S5) patterning a hemispherical hydrogel onto the electrospun amphipathic nanoporous membrane by crosslinking the hydrogel onto the electrospun amphipathic nanoporous membrane; and (S6) detaching the micromold from the hemispherical hydrogel patterned electrospun amphipathic nanoporous membrane, wherein the electrospun amphipathic nanoporous membrane comprises a hydrophobic layer and a hydrophilic layer, wherein the hydrophilic layer is manufactured by an electrospinning process on the hydrophobic layer using polyurethane and Poloxamer 407 dissolved to a concentration of 10% (w/v) and 10% (w/v) of solvent, wherein the hemispherical hydrogel is at a concentration selected from the group consisting of 2.5% (w/v), 5% (w/v), 10% (w/v) and 15% (w/v), and wherein the hemispherical hydrogel is configured to control release of the target compounds based on the hydrogel concentration.

7 . The method according to claim 6 , wherein the hydrogel contains the target compounds and at least one of gelatin methacryloyl (gel-MA), hyaluronic acid, Na-alginate and hyaluronic acid methacrylate (HAMA).

8 . The method according to claim 6 , wherein the target compounds are at a concentration selected from 1-2000 ng/mL.

9 . The method according to claim 6 ,
wherein the hydrophobic layer is manufactured by an electrospinning process using polyurethane dissolved to a concentration of 10% (w/v) solvent.

10 . The method according to claim 6 , wherein the hydrophilic layer has the surface wettability as the contact angle 82.89±1.3°.

11 . The method according to claim 6 , wherein the cross-linking is executed by exposing the hydrophilic functional groups of the hydrogel and the electrospun amphipathic nanoporous membrane to a UV light at a wavelength of 360 nm and an intensity of 10,000 mW/cm 2 ,
wherein the hydrophilic functional groups of the hydrogel are selected from the group consisting of —OH, —COOH, and —NH, and wherein the hemispherical hydrogel is patterned onto the hydrophilic layer of the electrospun amphipathic nanoporous membrane.

Assignees

• Knu Industry Cooperation Found

Inventors

• Lee Kwang Ho

Classifications

• A61K9/286

  Polysaccharides, e.g. gums; Cyclodextrin · CPC title

• A61K9/7007 Primary

  Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence) · CPC title

• A61K9/2086

  Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28) · CPC title

• A61K9/006

  Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays · CPC title

• A61K9/7023

  Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006) · CPC title